Your session is about to expire
Mao A vs Mao B
Introduction
For patients with depression or anxiety, certain drugs that inhibit the activity of monoamine oxidases (MAOs) can help in managing symptoms. MAO-A and MAO-B are two such enzymes present in our bodies, primarily found within nerve cells and are involved in mood regulation. They both break down different neurotransmitters but have a vital role in maintaining mental health. MAO-A is mainly responsible for breaking down serotonin and norepinephrine, two key neurotransmitters linked to emotions and mood regulation. On the other hand, MAO-B primarily breaks down dopamine, another crucial neurotransmitter related to pleasure sensation and reward mechanism. Inhibitors targeting these enzymes work by preventing their action, thus leading to an increase in the level of these respective neurotransmitters available for transmission between nerves.
Mao A vs Mao B Side By Side
| Attribute | Moclobemide | Selegiline |
|---|---|---|
| Brand Name | Moclobemide | Selegiline |
| Contraindications | Cannot be taken with SSRIs, tricyclic antidepressants, or certain pain medications without a waiting period due to risk of severe interactions. | Cannot be taken with SSRIs, tricyclic antidepressants, or certain pain medications without a waiting period due to risk of severe interactions. |
| Cost | $20-$40 for 30 tablets (150mg each) | $35 to $130 for 60 tablets (5 mg) |
| Generic Name | Moclobemide | Selegiline |
| Most Serious Side Effect | Symptoms associated with low mood or depression, signs of allergic reaction or severe skin reaction, visual disturbances, cardiovascular symptoms, sodium level changes in the body, severe nervous system reaction (Serotonin Syndrome). | Signs of allergic reaction or severe skin reaction, sudden episodes of falling asleep during everyday activities, significant changes in mood, unusual urges, hallucinations, increased blood pressure. |
| Severe Drug Interactions | SSRIs, tricyclic antidepressants, certain pain medications. | SSRIs, tricyclic antidepressants, certain pain medications. |
| Typical Dose | Not specified in the provided text, but as an MAO-A inhibitor, the dose would be adjusted based on the condition being treated and patient response. | Initiated at a lower dosage, around 5 mg per day, can be increased gradually up to a maximum of 40 mg/day. |
What is Mao A?
Monoamine oxidase (MAO) is a class of enzymes that catalyze the oxidation and deamination of neurotransmitters. They are divided into two types: MAO-A and MAO-B. Both play crucial roles in breaking down neurotransmitters, but they target different ones.
MAO-A primarily breaks down serotonin, norepinephrine, and dopamine - important mood-regulating chemicals. Its activity predominantly occurs in the gut, placenta, brain and peripheral adrenergic system where it regulates levels of these neurotransmitters to maintain emotional balance. Inhibiting its function could lead to an increase in these neurochemicals which can contribute towards treating conditions like depression.
On the other hand, MAO-B mainly metabolizes phenylethylamine (PEA), a trace amine with stimulant properties found in chocolate and cheese amongst others. It's mostly active within the brain and its inhibition leads to increased PEA availability which may have anti-depressant effects but also neuroprotective ones against Parkinson's disease.
Both types are targeted by drugs known as monoamine oxidase inhibitors (MAOI's) used to treat conditions including depression and Parkinson’s disease; however their use must be carefully managed due to potential interactions with certain foods or other medications.
What conditions is Mao A approved to treat?
Monoamine oxidase (MAO) A and B are two enzymes with different functions in the body:
- MAO-A primarily breaks down serotonin, norepinephrine, and dopamine. When levels of these neurotransmitters are too high or too low, it can lead to conditions such as depression.
- MAO-B mainly metabolizes dopamine. An excess of this enzyme can result in Parkinson's disease symptoms due to depleted dopamine levels. Consequently, inhibitors of both types of monoamine oxidases are used in treating various neurological and psychiatric disorders.
How does Mao A help with these illnesses?
Monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) are two types of enzymes present in various parts of the body including the brain, responsible for breaking down neurotransmitters like serotonin, norepinephrine, and dopamine. Both play critical roles in regulating mood, cognition, motivation, and movement.
However, they differ primarily in their substrate specificity and distribution. MAO-A preferentially breaks down serotonin and norepinephrine - neurotransmitters that have a substantial influence on mood regulation. Therefore an inhibitor of this enzyme can increase these neurotransmitter levels helping manage conditions like depression or anxiety.
On the other hand, MAO-B mainly metabolizes dopamine – a key player in reward-motivated behavior and motor functions. Hence inhibiting MAO-B is often beneficial for patients with Parkinson's disease as it helps maintain higher levels of dopamine for longer periods to manage symptoms.
What is Mao B?
MAO B, short for Monoamine Oxidase B, is an enzyme in the body that breaks down chemicals like dopamine, phenethylamine and other trace amines. It differs from its counterpart MAO A as it primarily degrades dopamine (a neurotransmitter associated with mood regulation and reward) in the brain. Unlike MAO A inhibitors which are typically used to treat depression due to their influence on serotonin levels, MAO B inhibitors have been found more useful for treating Parkinson's disease by preserving dopamine levels within the patient's brain. The effectiveness of these drugs can make them a preferred treatment option for patients who may not respond well to standard treatments for Parkinson's disease or those who wish to avoid certain side effects such as motor fluctuations related commonly seen with levodopa therapy.
What conditions is Mao B approved to treat?
MAO B inhibitors are recognized for their role in the management of several health conditions, including:
- Parkinson's disease: By blocking MAO-B enzymes, these medications may help improve motor symptoms and slow the progression of this neurodegenerative disorder.
- Depression: In some cases, MAO-B inhibitors can be used as part of a comprehensive treatment approach to manage depressive symptoms. They work by increasing the levels of certain chemicals in the brain that elevate mood.
How does Mao B help with these illnesses?
Monoamine oxidase B, or MAO-B, is an enzyme that plays a critical role in the metabolism of certain neurotransmitters in the brain. This includes dopamine, a key player involved in reward and motivation systems within our central nervous system. Unlike its counterpart monoamine oxidase A (MAO-A), which primarily breaks down serotonin and norepinephrine, MAO-B mainly metabolizes dopamine. Elevated levels of this enzyme have been linked to various neurological disorders such as Parkinson's disease and depression. Medications designed to inhibit MAO-B can increase dopamine availability in the brain, potentially improving symptoms associated with these conditions. Since it does not significantly affect serotonin or norepinephrine levels like MAO-A inhibitors do, it may be prescribed when a patient doesn't respond well to typical SSRI antidepressants or combined with them for a more comprehensive approach.
How effective are both Mao A and Mao B?
Monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) are two types of enzymes that play a significant role in the metabolism of neurotransmitters, especially those involved in mood regulation. Despite sharing 70% of their genetic sequence, MAO-A and MAO-B show different substrate preferences and inhibitor selectivity.
MAO-A prefers substrates such as serotonin, norepinephrine, dopamine, and tyramine; it is primarily responsible for breaking these down once they have transmitted their signal across the synapse. Overactivity or underactivity of MAO-A can lead to imbalances in these neurotransmitters which may contribute to conditions like depression or anxiety.
On the other hand, MAO-B primarily metabolizes phenylethylamine (a trace amine implicated in mood regulation), while also metabolizing dopamine to some extent. It's overactive state has been linked with neurodegenerative disorders like Parkinson's disease due to its potential role in oxidative stress within brain neurons.
In terms of inhibition for therapeutic purposes: selective MAO-A inhibitors like moclobemide are used mainly for treating depressive disorders while selective MAO-B inhibitors such as selegiline are utilized predominantly for managing Parkinson’s disease symptoms.
It should be noted that non-selective MAOI drugs which inhibit both enzymes were among the first type of antidepressants developed but due to risk factors associated with diet and drug interactions along with emergence of new classes having less side effects have led them being prescribed only after other treatment options have been exhausted.
While each enzyme plays an integral part within our nervous system functionality understanding how they work individually gives us insight into developing more effective therapies targeting specific pathologies related not just mental health but overall human well-being.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Mao A typically prescribed?
Although MAO-A and MAO-B are both types of monoamine oxidase enzymes, they have different preferences for breaking down neurotransmitters in the body. MAO-A preferentially breaks down serotonin and noradrenaline, while MAO-B primarily metabolizes dopamine. They also differ in their distribution throughout the body—MAO-A is more prevalent in the intestines and liver, whereas MAO-B is mainly found in the brain. It's important to note that inhibition or deregulation of either enzyme could lead to several health issues including depression, anxiety disorders, Parkinson’s disease or Alzheimer's disease. So adjusting levels of these enzymes should always be done under a healthcare professional's supervision.
At what dose is Mao B typically prescribed?
For the understanding of this comparison, it's important to note that MAO-A and MAO-B are not medications but enzymes that break down neurotransmitters in the brain. They're often targeted by certain types of drugs for conditions like depression or Parkinson's disease.
A drug targeting MAO-B is typically initiated at a lower dosage, which could be around 5 mg per day. If tolerated well and if deemed necessary by your healthcare provider, the dose can then be increased gradually to about 10 mg/day or even further up to a maximum of 40 mg/day. These doses are usually divided into two separate administrations spaced out over each day - morning and evening. It is crucial to keep in mind though that response should be continuously evaluated throughout treatment as excessive inhibition of these enzymes can lead to severe side effects like dangerously high blood pressure levels.
What are the most common side effects for Mao A?
Inhibitors of monoamine oxidase A (MAO-A) and B (MAO-B) are both drugs used in the management of neurological disorders. However, they differ subtly in their side effect profiles.
Common side effects associated with MAO-A inhibitors include:
- Anxiety
- Insomnia or sleep disturbances
- Dry mouth
- Nausea and digestive discomfort
- Diarrhea
- Decreased libido or sexual dysfunction
- Orthostatic hypotension (dizziness upon standing)
- Irritability
Whereas, common side effects for MAO-B inhibitors might feature:
-Somnolence (sleepiness/drowsiness)
-Dry mouth
-Nausea and indigestion
-Diarrhea
-Decreased appetite
-Joint pain
-Frequent urination
It's important to note that any adverse reactions should be reported to a healthcare professional promptly.
Are there any potential serious side effects for Mao A?
MAO-A and MAO-B are two different types of enzymes found in our bodies, which play a significant role in the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine. However, inhibitors for these enzymes can present varying side effects:
- Symptoms associated with low mood or depression: This is more likely with MAO-A inhibitors due to their action on serotonin and noradrenaline.
- Signs of allergic reaction or severe skin reaction: These could manifest from an adverse response to either type of inhibitor but are extremely rare.
- Visual disturbances: Blurred vision may occur; however it's not common and usually transient.
- Cardiovascular symptoms: Rapid heart rate or palpitations might be experienced due to increased levels of certain neurotransmitters. Shortness of breath or dizziness may also happen but less commonly.
- Sodium level changes in the body - A headache, confusion, slurred speech, severe weakness might suggest this change though it's very unusual.
- Severe nervous system reaction - Rigidity (stiff muscles), high fever, sweating confusion all point towards a rare condition known as Serotonin Syndrome that requires immediate medical attention.
Note that while these side effects can occur when using both MAO-A and B inhibitors they are generally quite uncommon and many patients tolerate these medications well without any major issues.
What are the most common side effects for Mao B?
When comparing Mao A to Mao B, it's important to note the different side effects that may occur. With MAO-B inhibitors:
- Possible dry mouth or increased salivation
- Occasional dizziness and light-headedness
- Nausea, mild stomach discomfort and loss of appetite could be experienced
- Insomnia might be a problem for some patients
- Some people may experience an increase in anxiety levels
- Heartbeat irregularities are rare but possible
- Confusion and agitation can happen, especially in higher doses
- Skin rash is uncommon yet possible
- Weight fluctuations aren't typically associated with these medications
- Increased urination isn't generally a concern with MAO-B inhibitors
- Headache can occasionally occur
-A muscle or joint pain isn't commonly seen as a direct effect of this medication.
Are there any potential serious side effects for Mao B?
It's important to note that MAO-A and MAO-B are types of enzymes rather than medications. Inhibitors for these enzymes (MAOIs) are available as medication, which perform different functions in the body. Focusing on MAO-B inhibitors, they are primarily used in Parkinson’s disease treatment. While generally well-tolerated, potential serious side effects may include:
- Signs of allergic reaction or severe skin reaction: hives, itching, fever; swollen glands; difficulty breathing; swelling in your face or throat
- Sudden episodes of falling asleep during everyday activities
- Significant changes in mood such as agitation or confusion
- Unusual urges like increased sexual urges and behaviors, an uncontrollable desire to gamble, binge eating
- Hallucinations and other psychosis-like behavior
- Increased blood pressure leading to severe headache, blurred vision.
If you experience any such symptoms while taking a MAO-B inhibitor medication it is advisable to seek immediate medical attention.
Contraindications for Mao A and Mao B?
Both Monoamine Oxidase A (MAO-A) and Monoamine Oxidase B (MAO-B) inhibitors are effective in treating certain neurological conditions, but should be taken under a doctor's supervision due to their potential for serious side effects. If you notice your condition worsening or any unusual symptoms appearing after starting these medications, please seek immediate medical attention.
Neither MAO-A nor MAO-B inhibitors can be taken if you are taking, or have recently stopped taking, other psychiatric drugs like selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, or certain pain medications. Always inform your physician about all the medicines you are currently on before starting treatment with these classes of drugs; it is often necessary to allow a period of about 2 weeks to clear out the previously used drug from your system before initiating treatment with MAO-A or MAO-B inhibitors to prevent dangerous interactions.
How much do Mao A and Mao B cost?
Please note that MAO-A and MAO-B are not drugs themselves but types of enzymes in the body that metabolize certain medicines. They're often a consideration when prescribing medication for conditions such as depression or Parkinson's disease.
MAO inhibitors, which inhibit these enzymes, come in selective forms (targeting either MAO-A or MAO-B) and nonselective forms (which target both).
For instance:
- Selegiline is a selective MAO-B inhibitor. The cost for Selegiline oral tablet 5 mg can range from $35 to $130 for 60 tablets—roughly $1–$4/day depending on your dose.
- Moclobemide is an example of an MAO-A inhibitor. A pack containing 30 tablets of Moclobemide (150mg each) costs around $20-$40—approximately between $0.70 and $1.30 per day.
Thus, if you are prescribed a higher dosage range for Selegiline, then Moclobemide may be less expensive on a per-day treatment basis considering similar dosages.
However, it's essential to remember that cost should not be the only factor determining which medicine or enzyme inhibitor type is best suited for you; efficacy and side effects are vital considerations too.
Popularity of Mao A and Mao B
Monoamine oxidase A (MAO-A) and Monoamine oxidase B (MAO-B) are both enzymes that play significant roles in the human body. They are involved in the breakdown of neurotransmitters, such as serotonin, norepinephrine, and dopamine.
The inhibition of MAO-A has been found to be effective for treating depression; hence medications targeting this enzyme have become quite prevalent. The use of MAO-A inhibitors has remained relatively stable over time due to their efficacy, although they may not always be first-line treatments due to potential interactions with certain foods or other drugs.
On the other hand, MAO-B inhibitors primarily target dopamine breakdown and have been utilized more specifically for conditions like Parkinson's disease rather than depression. Their usage is slightly less common overall compared to MAO-A inhibitors but has seen an increase in recent years due to advancements in understanding neurological disorders better and developing targeted treatments.
Conclusion
Both MAO-A (monoamine oxidase A) and MAO-B (monoamine oxidase B) have critical roles in the metabolism of monoamines, which include neurotransmitters such as serotonin, norepinephrine, and dopamine. Both enzymes are backed by extensive research demonstrating their crucial part in regulating these neurotransmitters' levels. However, they target different sets of monoamines: MAO-A primarily metabolizes serotonin and norepinephrine while MAO-B is primarily responsible for breaking down dopamine.
Due to these differences in action, inhibitors of each type can be used under varied circumstances. For instance, drugs inhibiting the action of MAO-A like Moclobemide can be a first-line treatment option for conditions like depression due to its ability to increase serotonin and norepinephrine levels. On the other hand, drugs that inhibit MAO-B activity like Selegiline may be added on or considered for patients with Parkinson's disease who require increased dopamine availability.
The side effect profiles between agents targeting either enzyme are similar but will depend largely on their selectivity and dosage. Both classes must be administered with caution due to potential serious interactions with certain foods or medications leading to a hypertensive crisis or serotonin syndrome.
Generic versions are available for many drugs acting on both types of enzymes representing significant savings especially for those paying out-of-pocket. As with any medication affecting brain chemistry an adjustment period may be required before noticeable effects occur.
Patients initiating therapy should closely monitor symptoms when starting treatment; seek immediate medical help if there is worsening mood or thoughts about self-harm.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Udemgba, C., Johnson, S., Stockmeier, C. A., Luo, J., Albert, P. R., Wang, J., … Ou, X.-M. (2013, August 5). The Expression of KLF11 (TIEG2), a Monoamine Oxidase B Transcriptional Activator in the Prefrontal Cortex of Human Alcohol Dependence. Alcoholism: Clinical and Experimental Research. Wiley.http://doi.org/10.1111/acer.12229
- Ramsay, R. R. (2016, August). Molecular aspects of monoamine oxidase B. Progress in Neuro-Psychopharmacology and Biological Psychiatry. Elsevier BV.http://doi.org/10.1016/j.pnpbp.2016.02.005
- Foley, P., Gerlach, M., Youdim, M. B. H., & Riederer, P. (2000, January). MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?. Parkinsonism & Related Disorders. Elsevier BV.http://doi.org/10.1016/s1353-8020(99)00043-7
- Abell, C. W., & Kwan, S.-W. (2000). Molecular characterization of monoamine oxidases A and B. Progress in Nucleic Acid Research and Molecular Biology. Elsevier.http://doi.org/10.1016/s0079-6603(00)65004-3
- Finberg, J. P. M. (2018, November 1). Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease. Journal of Neural Transmission. Springer Science and Business Media LLC.http://doi.org/10.1007/s00702-018-1952-7
- Jarrott, B., & Vajda, F. J. E. (1987, June). The current status of monoamine oxidase and its inhibitors. Medical Journal of Australia. AMPCo.http://doi.org/10.5694/j.1326-5377.1987.tb120442.x
- Thébault, J. J., Guillaume, M., & Levy, R. (2004, October). Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Wiley.http://doi.org/10.1592/phco.24.14.1295.43156
- Tan, Y.-Y., Jenner, P., & Chen, S.-D. (2022, February 15). Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. Journal of Parkinson's Disease. IOS Press.http://doi.org/10.3233/jpd-212976
- Bainbridge, J. L., Lee Page, R., II, & Ruscin, J. M. (2008, August). Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors. Neurologic Clinics. Elsevier BV.http://doi.org/10.1016/j.ncl.2008.05.002